# Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

> **NCT04725188** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 255 (actual)

## Conditions studied

- Metastatic Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab/Vibostolimab coformulation
- **DRUG:** Docetaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04725188
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-20
- **Primary completion:** 2023-01-26
- **Final completion:** 2024-10-17
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725188, "Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04725188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*